Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Recruiting

Phase 2

VolrustomigStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sponsor:

AstraZeneca

Code:

NCT06535607

Conditions

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)

Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Volrustomig

Cisplatin

Carboplatin

Paclitaxel

5-FU

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-24. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-05-26.